Publication
Ribosomal Stalk Protein Silencing Partially Corrects the Delta F508-CFTR Functional Expression Defect
Downloadable Content
- Persistent URL
- Last modified
- 02/25/2025
- Type of Material
- Authors
- Language
- English
- Date
- 2016-05-01
- Publisher
- Public Library of Science
- Publication Version
- Copyright Statement
- © 2016 Veit et al.
- License
- Final Published Version (URL)
- Title of Journal or Parent Work
- ISSN
- 1544-9173
- Volume
- 14
- Issue
- 5
- Start Page
- e1002462
- End Page
- e1002462
- Grant/Funding Information
- This work was supported by Howard Huges Medical Institute (www.hhmi.org) Physician-Scientist Early Career Award P/S ECA 57005927 and Cystic Fibrosis Foundation (www.cff.org) Research Grant MILLER08G0 to JLH, the Cystic Fibrosis Foundation R464-CR11 and National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, www.niddk.nih.gov) P30DK072482 to EJS, NIH-NIDDK R01DK75302, Cystic Fibrosis Canada (www.cysticfibrosis.ca) and Canadian Institutes of Health Research (www.cihr-irsc.gc.ca) to GLL.
- Supplemental Material (URL)
- Abstract
- The most common cystic fibrosis (CF) causing mutation, deletion of phenylalanine 508 (ΔF508 or Phe508del), results in functional expression defect of the CF transmembrane conductance regulator (CFTR) at the apical plasma membrane (PM) of secretory epithelia, which is attributed to the degradation of the misfolded channel at the endoplasmic reticulum (ER). Deletion of phenylalanine 670 (ΔF670) in the yeast oligomycin resistance 1 gene (YOR1, an ABC transporter) of Saccharomyces cerevisiae phenocopies the ΔF508-CFTR folding and trafficking defects. Genome-wide phenotypic (phenomic) analysis of the Yor1-ΔF670 biogenesis identified several modifier genes of mRNA processing and translation, which conferred oligomycin resistance to yeast. Silencing of orthologues of these candidate genes enhanced the ΔF508-CFTR functional expression at the apical PM in human CF bronchial epithelia. Although knockdown of RPL12, a component of the ribosomal stalk, attenuated the translational elongation rate, it increased the folding efficiency as well as the conformational stability of the ΔF508-CFTR, manifesting in 3-fold augmented PM density and function of the mutant. Combination of RPL12 knockdown with the corrector drug, VX-809 (lumacaftor) restored the mutant function to ~50% of the wild-type channel in primary CFTRΔF508/ΔF508 human bronchial epithelia. These results and the observation that silencing of other ribosomal stalk proteins partially rescue the loss-of-function phenotype of ΔF508-CFTR suggest that the ribosomal stalk modulates the folding efficiency of the mutant and is a potential therapeutic target for correction of the ΔF508-CFTR folding defect.
- Author Notes
- Keywords
- SACCHAROMYCES-CEREVISIAE
- Small interfering RNAs
- IN-VITRO
- Yellow fluorescent protein
- HeLa cells
- QUALITY-CONTROL
- TRANSMEMBRANE CONDUCTANCE REGULATOR
- Immunoblotting
- NONOPTIMAL-CODON USAGE
- Transfectin
- Biosynthesis
- ENDOPLASMIC-RETICULUM
- Biology
- CYSTIC-FIBROSIS
- TRANSLATION ELONGATION
- Elongation factors
- Biochemistry & Molecular Biology
- PLASMA-MEMBRANE
- Membrane proteins
- Life Sciences & Biomedicine
Tools
- Download Item
- Contact Us
-
Citation Management Tools
Relations
- In Collection:
Items
| Thumbnail | Title | File Description | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|---|
|
|
Publication File - rpx7w.pdf | Primary Content | 2025-02-20 | Public | Download |